Samuel Strader

Journal Article bioRxiv · April 17, 2024 BACKGROUND: LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on endolysosomes in phagocytic cells to promote some types of immunological res ... Full text Link to item Cite

Anionic nanoplastic contaminants promote Parkinson's disease-associated α-synuclein aggregation.

Journal Article Sci Adv · November 15, 2023 Recent studies have identified increasing levels of nanoplastic pollution in the environment. Here, we find that anionic nanoplastic contaminants potently precipitate the formation and propagation of α-synuclein protein fibrils through a high-affinity inte ... Full text Link to item Cite

The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease.

Journal Article Biochem Soc Trans · April 26, 2023 The accumulation of aggregated α-synuclein in susceptible neurons in the brain, together with robust activation of nearby myeloid cells, are pathological hallmarks of Parkinson's disease (PD). While microglia represent the dominant type of myeloid cell in ... Full text Open Access Link to item Cite

HepaCAM controls astrocyte self-organization and coupling.

Journal Article Neuron · August 4, 2021 Astrocytes extensively infiltrate the neuropil to regulate critical aspects of synaptic development and function. This process is regulated by transcellular interactions between astrocytes and neurons via cell adhesion molecules. How astrocytes coordinate ... Full text Link to item Cite